The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / ACR/ARHP Annual Meeting 2012: New Research Into Stem Cell Therapy and Drugs May Lead to Breakthrough Treatments for Osteoarthritis

ACR/ARHP Annual Meeting 2012: New Research Into Stem Cell Therapy and Drugs May Lead to Breakthrough Treatments for Osteoarthritis

February 1, 2013 • By Susan Bernstein

  • Tweet
  • Email
Print-Friendly Version / Save PDF

Also effective for use in treating chronic OA pain are oral drugs like duloxetine, Dr. Hochberg said, and among opioids, tramadol. Tramadol carries the risk of both minor and major adverse effects, including dependence, he said. “If you’re going to use tramadol, you start low and increase the dose slowly to ensure your patient tolerates the therapy,” he noted. Opioids other than tramadol should be avoided in OA due to adverse effects, except in patients who are either unwilling to undergo total joint arthroplasty or have contraindications to the procedures, Dr. Hochberg said.

You Might Also Like
  • ACR/ARHP Annual Meeting 2012: Will Novel Strategies Lead to Breakthroughs in Treating Osteoarthritis?
  • Mesenchymal Stem Cell Therapy May Help Slow, Repair Degenerative Signs of Osteoarthritis, Musculoskeletal Disease
  • Research Into Causes of Systemic Vasculitis May Lead to Targeted Treatments Say Rheumatologists at the 2013 ACR/ARHP Annual Meeting
Explore This Issue
February 2013
Also By This Author
  • Autoimmune Inflammation Increases Risk of Heart Disease

Stem Cell Therapy

Stem cell therapy may be one potential way to restore damaged cartilage and even bone lesions in OA-affected joints, said Rocky Tuan, PhD, director of the Center for Cellular and Molecular Engineering at the University of Pittsburgh Medical Center. Stem cell research in the U.S. has focused on animals, he said. “Unfortunately, there are no specific, longitudinal studies of the efficacy of stem cell therapy in animals, so it’s tough to make that transition to humans,” he said. There are ethical concerns about using embryonic stem cells, so researchers now focus on applications of multipotent stromal cells, or MSCs, autologous cells that may be harvested from sources like bone marrow or umbilical cord blood.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Active MSCs are potentially very useful for OA, said Dr. Tuan. “A stem cell cannot just sit around and be a stem cell. They have to get up and do something!” he joked. MSCs differentiate into other cells like osteoblasts and chondrocytes that may be used to replace OA-damaged tissues, said Dr. Tuan.

MSCs are effective at making new cartilage, but only in 1-mm strands, so Dr. Tuan and his colleagues designed a scaffold to hold stem cells around the joint, he explained. They modified electrospinning, a technique originally designed for the textile industry, to create a scaffold of polymer nanofibers that resembles the cartilage structures within knees. “The cells love this. The cells are sprayed in and are quite happy to latch onto the fibers,” he said. They tested the technique on a miniature pig’s deteriorated knee joint. “It looks promising. We were able to grow cartilage, put it in the knee, and repair the defect,” he said. Dr. Tuan also described the fabrication of an MSC-based osteochondral construct to repair a damaged knee joint in a miniature pig. The joint had an 8-mm lesion in the femoral head, which the researchers filled with a gelatin-based hydrogel that was then illuminated using a dentist’s light. Dr. Tuan showed stained images of the construct after three days that illustrated the viability of MSCs in this application.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Pages: 1 2 3 | Single Page

Filed Under: Conditions, Meeting Reports, Osteoarthritis Tagged With: Osteoarthritis, Research, Stem Cells, TreatmentIssue: February 2013

You Might Also Like:
  • ACR/ARHP Annual Meeting 2012: Will Novel Strategies Lead to Breakthroughs in Treating Osteoarthritis?
  • Mesenchymal Stem Cell Therapy May Help Slow, Repair Degenerative Signs of Osteoarthritis, Musculoskeletal Disease
  • Research Into Causes of Systemic Vasculitis May Lead to Targeted Treatments Say Rheumatologists at the 2013 ACR/ARHP Annual Meeting
  • ACR/ARHP Annual Meeting 2012: New Treatments and Strategies Emerge for Osteoporosis

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)